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Executive Summary
Within stable economic societies, polypharmacy has become a phenomenon that can be
more harmful, although medications prescribed are with good intentions. Education is integral to
nursing responsibilities; it is an intervention tool to help patients affected by polypharmacy. The
interest in polypharmacy stems from witnessing the lack of patient education within the acute
setting, and the lack poses a greater risk for adverse drug events (ADEs). The healthcare
industry’s responsibility is to help alleviate the adverse effects that polypharmacy causes, such as
falls, adverse drug reactions, hospitalizations, mortality, and cognitive mental (Fried, 2014).
A new performance improvement project (PI) will be implemented to improve patient
education on polypharmacy. Each department will have its own goals, but this focus is on the
emergency department (ER). In the ER, the nurse is the first to recognize the effects of
polypharmacy; the charge nurse and provider should be immediately notified so that a care plan
with appropriate interventions can be quickly implemented. Patients must be educated on new
medications that include dosages, side effects, and potential risks, and this should be an essential
teaching tool for all healthcare staff. A courtesy visit copy will be provided to the patient’s
primary care provider with an alert to the ADE or the potential. The plan will follow the patient
until discharge from the ER or an inpatient setting. Evaluation will be after a thirteen-week
implementation through chart reviews, patient follow-up, and the number of polypharmacy
related admits. After implementing this PI project, the goal is to improve the patient’s knowledge
base on the practice of polypharmacy, hoping for successful outcomes by potentially reducing
ADEs and improving patient awareness. Nurses are responsible for educating patients and their
families on how to take control of their health by knowing their disease processes and each
prescription taken by the patient.
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Rationale

According to Melnyk & Fineout-Overholt, patient-centeredness is required for patient
preferences and values in evidence-based decision-making (pg. 227). Reliable studies and
research that lead to evidence-based practice must be achievable and current (Melnyk & FineoutOverholt, 2018, pg.226). With research into polypharmacy, the focus is on the best obtainable
outcome keeping in mind patient safety and education on self-awareness about their health. A
patient in the right state of mind would prefer optimal health with little to no prescriptions (Rx) if
possible. Fortunately, with the present health advances, Rxs have been able to help many
individuals with acute and chronic ailments. However, on the other side of the spectrum, some
patients have been plagued with multiple diseases (multimorbidity) requiring numerous Rx,
hence the term polypharmacy. Each new Rx requires new education and the more Rx individuals
take because of multimorbidity, the more education the medical professional would be ethically
bound to provide. As stated by Melnyk & Fineout-Overholt, page 227, “the clinician must act in
the patient’s best interests and do as little harm and as much good as possible.

An adverse drug reaction (ADR) unrecognized by clinicians may lead to what is known
as a “prescribing cascade” when a new prescription is given to treat the ADR, presenting an
additional risk to multimorbid patients (Menditto et al., 2019). Unfortunately, this scenario leads
to polypharmacy and is accepted in the United States. Multimorbid patients usually require more
than one specialist. Patients are not diligent about self-monitoring their medications or keeping
an adequately updated list risk therapeutic equivalents to treat an illness or symptoms. According
to an article published in the Journal of the American Geriatrics Society, sixty-six percent of the
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2402 patients studied were discharged from the hospital setting and were released with a
potentially inappropriate medication (PIM) (Weir et al., 2020).

Literature Synthesis
There are dilemmas surrounding the appropriate management of deprescribing in
multimorbid patients who practice polypharmacy (Allatoona et al., 2016). Studies
define polypharmacy as taking five or more medications or an excessive number of drugs
(Martinez-Gomez et al., 2018) (Wu et al., 2021). Deprescribing is defined as safely and
consistently decreasing unnecessary medicines that no longer benefit the patient (Ailaboni et al.,
2016). Barriers for comorbid patients and healthcare professionals are the lack of guidelines for
safe prescribing methods and deprescribing interventions; most policies are geared toward a
single disease paradigm (Muth et al., 2021) (Payne, 2016) (Wu et al., 2021). Studies have
concluded that polypharmacy dramatically affects a patient's quality of life (QOL), and
deprescribing medications with favorable lifestyle changes increase the QOL (Martinez-Gomez
et al., 2018) (Wu et al., 2021). Even though there are conflicts such as time and no incentive for
physicians and pharmacists, regular clinical medication reviews (CMRs) should be performed to
help improve QOL and reduce adverse drug reactions (ADEs) (Earl et al., 2020) (Piccoliori et
al., 2021).
Although some physicians accept pharmaceutical benefits and pharmacies receive
incentives for many prescriptions, business models need to be changed for the patient's benefit
and to help curb polypharmacy (Laberge et al., 2021). Due to the cost of intervention
implementation, and limited interest from physicians, the deprescribing implementation is
challenging (Laberge et al., 2021). Although limited prediction models exist, there are tools to
help screen electronic health records (EHRs) for potentially inappropriate medications (PIMs),
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including screening tools of older persons' potentially inappropriate prescriptions (STOPP),
Beers Criteria, Drug Burden Index (DBI), with quality indicators, and codes to help identify
chronic diseases (ICPC) (Earl, 2020) (Muth et al., 2019) (Piccoliori et al., 2021) (Wu et al.,
2021). Using the Beers Criteria shows that 6.1% of prescriptions may be a PIM (Piccoliori et al.,
2021).
Evidence shows that some patients who practice polypharmacy and take certain
classifications of medications are more prone ADEs or drug-to-drug interactions, increasing
mortality and decreasing the QOL (Martinex-Gomez et al., 2018). There is a 58% correlation
between patients who suffer from depression, and practice polypharmacy is more likely to suffer
an ADE; therefore, patients who suffer from depression should be subject to frequent CMRs
(Burger et al., 2017) (Doos et al., 2014) (Piccoliori et al., 2021). Studies conclude that
cardiovascular deaths tend to increase with the number of medications taken and decrease
through safely deprescribing and favorable lifestyle deviations (Martinez-Gomez et al., 2018).
Lifestyle behaviors should be measured against medication categories to develop effective
strategies and proper patient-oriented goals,
6.6% of hospital admissions can be attributed to ADEs due to polypharmacy (Ciummo et
al., 2020). Evidence shows that 57% of patients with four or more conditions have additional
prescriptions at discharge from the inpatient setting (Doos et al., 2014). Also, there is a 7.8%
readmission rate within thirty days after release for comorbid patients who practice
polypharmacy (Pereira et al., 2021). Because of the risks of developing harmful outcomes,
reliable methods must be in place to identify those at risk for polypharmacy ADEs at discharge
(Muth et al., 2021). Because of these instances, the need for healthcare individuals to recognize
polypharmacy is imperative to alleviate the harmful effects polypharmacy can create.
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There is an urgent need to help teach patients self-efficacy and set the standard for shared
decision-making with patient preferences and goal setting (Muth et al., 2019). All the research to
date it is strongly suggested the need for coordinated care between physicians for effective,
sustainable patient outcomes (Doors et al., 2014) (Bleijenberg et al., 2017) (Ailabonuni et al.,
2016) (Earl et al., 2020) (Burger et al., 2017) (Muth et al., 2019). Health care professionals
should deliver adequate treatment communication, safety instructions, strategies for self-care,
follow-ups, and integrated care to develop optimal patient outcomes and monitor intervention
effectiveness (Bleijenberg et al., 2017) (Muth et al., 2019). It has been proven that interventions
through healthcare-led programs with follow-ups, family partnerships, and patient-centeredness,
comorbid patients have a higher QOL and better outcomes (Bleijenberg et al., 2017). All the
studies concluded that an integrated approach and standard practice guidelines are essential for
physicians treating multimorbid patients who practice polypharmacy.
Stakeholders
In the practice setting, the stakeholders, which include the physicians, nurses,
administrators, payment sources such as public and private insurances, patients, and families,
should be aware of the possibility of a PIM prescribed on any given day. Patients trust the
medical professional to make the right decisions to help eliminate the PIMs; protocols should be
in place and followed. A change is needed to help eliminate the effects of polypharmacy and
allow the patients to be free from ADEs. If patients are educated on the need for change and
physicians are informed on the necessity to de-prescribe safely, polypharmacy and the potential
for ADEs will become less common.
Implementation
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A new program implementation must begin at the top and may offer an incentive for
compliance and participation. According to one study, the lack of consistency seems to be the
biggest challenge when implementing a new project facility-wide (Mathieson et al., 2019).
Polypharmacy has become an interest to many in healthcare not only because of the adverse drug
events (ADEs), other considerations include cost, patient culture, patient adherence, and
medication effectiveness. Nurses must be educated on the importance of medication teaching,
recognizing polypharmacy, and when more than the standard intervention is warranted. Not only
should more patient education be required, but the healthcare workers should become efficient in
recognizing the effects of polypharmacy and key the phrase "more is not always better." With
more research into polypharmacy, the future of healthcare and "Big pharma" will have to
conform to patient consideration when prescribing.

Before the actual implementation of the project, the nursing staff must be educated on
how to recognize polypharmacy and ADEs. The nursing staff should be familiar with the most
recent copy of the Nurses Drug Handbook and be alert to the need for continuing education after
discharge. Nurses must be trained and diligent in identifying and deterring potential drug-to-drug
interactions. The nurse education will be assigned and required before PI project implementation.

During brief training sessions, the nurses will be trained to recognize polypharmacy and
any possible ADE admitted to the ER. For analysis, the nurse will reconcile the patient's current
medications for the physician and the nursing team. Medication reconciliation and education are
essential and a nurse’s priority if drugs are administered while patients are under their care. Not
properly reconciling patient medication may lead to duplicating existing therapies, incorrect
dosages, and omitting needed medicines at discharge time (Medication, 2019). The medication
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reconciliation taskbar will remain highlighted until completed by the primary nurse. The charge
nurse and attending ER physician are alerted to the findings. During the time in the ER, the
primary nurse will ascertain the patient's and family's knowledge based on the currently
prescribed medications and determine if further intervention is needed. At the time of discharge
from the ER, the patient will provide verbal and written education to the patient, caretaker, or
family on any new medications the patient is prescribed. A 2019 article titled Medication
Reconciliation states that an adverse drug event is more likely to occur after a hospital discharge.
If the patient is admitted to the floor, the hospitalist and new primary nurse will be aware of the
findings. As a courtesy, the primary physician will be notified along with an alert to the ADE or
possible ADE.
Timetable/Flowchart
The timetable/flowchart, as seen in Appendix B, will be as follows. Before anything is
implemented on the floor, the nurses must attend the Foundations of Polypharmacy session.
There will be an option of four different times, lasting approximately one and a half hours. This
discussion will be presented by nursing leaders and the pharmacist. These sessions will be
offered during the first two weeks of this implementation. During the third through fifth weeks,
several modules will be completed on nursing responsibilities through continuing education
issued by the education department. In the sixth through the thirteenth weeks, the
implementation will begin, and at this time, nurse leaders will be observant and available to
answer questions. As discussed in data collection, after the thirteenth week, data will be collected
through chart audits, follow-up phone calls, leader rounding, and comparable ADEs before
implementation will be compared. Information from follow-up phone calls will be whether the
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patient received proper medication education, verbal and written and whether the patient fully
understood and retained the education and information provided by the staff.
Data Collection Methods/Planned
After the first thirteen-week period ends, chart review will determine if the nurses
recognized ADEs, which will be noted in the chart by the physician and charge nurse being
notified. Chart reviews will be completed on patients with a medication reconciliation of five or
more mediations. The chart review or patient phone interviews will determine if proper
pharmaceutical education was given. Measurable data will compare ADEs in the same period
from one year prior. If the ADE admit percentages are less and adequate education is noted in the
charts, it will be concluded that the PI project is a success. Evaluations will continue, and
improvements will be implemented as needed.
Cost Benefit Discussion
The United States spends over $500 billion yearly on prescription drugs, and at this time,
the cost is rising three times the inflation rate (Joseph, 2021). A UK global study suggested that
guidelines for most clinical settings are not geared toward co-morbid patients but rather for a one
disease process (Payne, 2016). An adverse drug reaction (ADR) unrecognized by clinicians may
lead to what is known as a “prescribing cascade” where new prescriptions are given to treat the
ADR, presenting an additional cost and risk to multi-morbid patients (Menditto et al., 2019).
Healthcare professionals need to scale up deprescribing interventions and help reduce the cost
associated with polypharmacy, which may enhance patient QOL (Laberge et al., 2021).
Polypharmacy is related to adverse drug events, which studies have shown can cause
extended hospital stays (Fukuba et al., 2020). Studies have demonstrated adverse drug events
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may include non-compliance, falls, overdoses, and drug interactions. Also, the Centers for
Medicaid and Medicare Services follow the Hospitals Readmission Reduction Program, which
may affect the hospital's profit if a patient is readmitted (Hospital, 2021). This ensures hospital
policy is followed because it affects the hospital profit margin, making medication safety another
sustainable factor for implementation.
Overall Discussion/Results
Evidence-based practice is crucial to researching an ethical and safe solution to a
problem such as polypharmacy. There have been several instances when patients have not seen
the provider for an extended period and health statuses have changed, but the medication
regimen has not; therefore, adverse effects are frequently witnessed by ER staff. It is a daily and
personal experience to educate patients and families about home medications after a
polypharmacy-associated incident in the emergency room. A qualitative study cited that one of
the main reasons for non-compliant patients is that they do not know why they are taking the
medication or its use (Kobue et al., 2017). The ER is a frequent safety net in healthcare,
including polypharmacy, therefore, making the ER a good start for polypharmacy education. It
won’t be easy to follow up on positive outcomes unless there is adherence to the implementation
guide given for this PI project. Suppose this benchmark PI project can be implemented in the
future. In that case, it is with the hope that other healthcare professionals will see the need for
polypharmacy education and the patient’s condition for an improved QOL.
Recommendations
While protocols prevent healthcare workers from inflicting potential harm, they benefit
the patient and help produce superior outcomes. According to the U. S. Preventive Services Task
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Force (USPSTF), protocols are the backbone of the medical industry and are based on evidencebased practice (United, 2022). Implementing this project into protocol is a step to unraveling the
errors occurring with polypharmacy. Furthermore, a successful endeavor will take strategic and
coordinated care of all involved, from administration, doctors, nurses, patients, and families.
Implementing this project is a step in the right direction to help improve patients’ QOL. While
polypharmacy education is genuinely needed and essential, it is imperative to emphasize the
value of self-efficacy and the responsibility individuals have over their health. The Joint
Commission has made medication safety a 2022 goal making this implementation even more
critical now.
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Appendix A
Literature Evaluation Table
Clinical Question (PICOT): In comorbid patients how does the practice of polypharmacy compared to only clinically necessary medications affect
health and well-being during a period of study?
Citation:
author(s),
date of
publication&
title

KS#1
Doos, L. et
al. 2014,
Multi-drug
therapy in
chronic
condition
multimorbi
dity: a
systematic
review

Purpose of
Study

Conceptual
Framework

Synthesize
the current
evidence on
patterns of
multi-drug
prescribing
in family
practice

Intervention
s that lead
to an
effective
outcome
involving
comorbid
patients
involved in
polypharma
cy

Design/
Method

Sample/Se
tting

Major
Variables
Studied and
Their
Definitions

SR

N=11

IV=CC

5 databases
searched.
Articles in
English
dated 20032011.
Surveys,
questionnai
res, EHRs,
prescription
records,
exploratory
analysis’,
Crosssectional
studies

1017
articles
identified,
198
articles
screened,
23 papers
assessed
and 11
studies
met
criteria

Coordinated
care, the need
for CC by
physicians
who have
patients with
comorbidities
requiring
multiply
specialists
and multidrug therapies

Studies
include
18yrs and
older

Measurement of
Major Variables

(CC)6 chronic
conditions
studied
With(MDT)
multi-drug
therapies (taking
5 or more Rx at
one time)

Data
Analysis

CI=confidence
interval

(CC)&(MDTT)
with depression

OR=Odds
Radio

OR=4.32, 95%
CI 1.4-5.96
OR=4.32, 95%

(X)=
mean

CC with
depression

Study Findings

CI=3.13-5.96
OR=0.58, 95%
CI0.35-0.96
OR=0.3

DV= FR

OR=1.07, 95%

further
research to
deliver
appropriate
care

CI 1.03-1.11

Appraisal of Worth to Practice
Strength of the Evidence =
1) Level of evidence +
2) Quality [study strengths and
weaknesses])
3) YOUR Recommendations

Evidence LEVEL I
Weaknesses:
Terminology
Challenges:
potential over-lap between multiple
drug therapies and specific term
polypharmacy. Polypharmacy can
focus on older populations
Weakness was identified, then
combinations were used in the search
Review:

OR=0.94, 95%

The polypharmacy approach may be
harmful, including drug interactions,
increased mortality, cost

CI 0.90-.099

Conclusion/recommendation:

X=ages

Healthcare professionals need further
development and studies to better
manage comorbid patients practicing
polypharmacy.

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index,
CI-confidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDVdependent variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVELPCD-Netherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic
review, STOPP- screening tool of older persons potentially inappropriate prescriptions,
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KS#3
Ailabouni,
N. General
practitioner
s’ insight
into
deprescribi
ng for the
multimorbi
d older
individual:
a
qualitative
study,
2016,
70(3), 261–
276

Explore
general
practitioners
’ (GP)
opinions &
awareness
of
describing
in an older
multimorbid
patient
practicing
polypharma
cy.

The study
highlights
the lack of
clarity
around
deprescribin
g in
multimorbid
ity and
guidelines
may help to
clarify
evidencebased
medicine
relating to
controversia
l areas and
could
decrease the
variations

Qualitative
study

Random
sampling

Face to face
in depth
interviews
with GPs
that was
transcribed
verbatim
and for
thematic
analysis.

40 GPs
contacted
10 GPs
consented
to the
study

IV: GP
general
practitioners
GP opinions
on safely
deprescribing
in
multimorbid
patients

DV: Ddeprescribing
Lack of
clarity on
deprescribing
in comorbid
patients
practicing
polypharmacy

Research team
(PhD) in
medical setting

Constant
comparison
techniques

IQ- interview
questions

Analysis using
nVivo software

IQ that explored
GPs challenges
when
prescribing for
older adults

Gibbs
Qualitative data
analysis

HP-hypothetical
profile
GPs asked to
review, reduce,
dc or change
medications in
the HP

Results were the
opinions of GPs
of interview
questions.

A table was made
to for each
medicine to look
for similarities or
differences in
preventive and
symptomatic
medicines

Evidence Level: VI
Strengths:
Using the HP GPs shared their present
knowledge of evidence based on
medicine without having to consider
realistic pressures. Face to face
interviews GPs may have been more
comfortable stating their unbiased
opinions.
Limitations:
GPs may have stated socially desirable
responses, which does not reflect their
routine clinic practice. Using the HP
test results were unavailable for
consideration
Conclusion:
The study highlights the consensus for
deprescribing guidelines, which GPs
can use to guide their decision making
when reviewing medication regimens
Recommendations:
Use this study as a keeper study as it
shows insights into GPs views on the
practice of deprescribing. This can
assist with PICOT into understanding
how patients will understand the process
of deprescribing

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,
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KS#4
Earl, T. R.,
Katapodis,
N. D.,
Schneiderm
an, S. R., &
ShoemakerHunt, S. J.
(2020).
Using
Deprescribi
ng Practices
and the
Screening
Tool of
Older
Persons’
Potentially
Inappropria
te
Prescription
s Criteria to
Reduce
Harm and
Preventable
Adverse
Drug
Events in
Older
Adults. Jou
rnal of
Patient
Safety,
S23–S35.
KS 5
Burger, H.,
Holvast, F.,

The effect
of
intervention
for
deprescribin
g and using
the STOPP
criteria on
preventable
ADEs for
older adults.
Pge 23
under
methods

Association
between
depressin
and

effect of
intervention
s for
deprescribin
g and using
the STOPP
criteria on
preventable
ADEs for
older
adults?
Deprescribi
ng is an
approach
and the
STOPP
criteria are
used in a
screening
tool that
was part of
the
intervention
s reviewed.
Pg 23 in
methods

SR using 2
data bases
with
literature
published
220082018.
Included 26
studies,
with one
systematic
review.
Studies
include
RCTs,
decision
support
tools,
education
intervention
s,
medication
reviews by
pharmacist
and
physicians.
Economic
studies.
Used
STOPP
screening

N=14
studies
for table
1,
evaluatin
g
interventi
ons
regarding
deprescri
bing

In primary
care late life
depression
leads to

Cohort
study with
a cross
sectional

N=4477

N=12
studies
and 1 SR
for
STOPP
criteria

IV- STOPP
criteria/depres
cribing to
reduce ADEs
from
polypharmacy
DV-research
needed on
effectiveness
of tools such
as STOPP to
eliminate
PIMs and
reduce ADEs

STOPP criteria
Decreased
hospitalizations
Medication
reductions
Percentage
decreases

Percentages
reductions,
ratios, clinical
outcome,
reduced ADEs,
SR of literature,
effects of
interventions,
observation of
economic and
clinical
outcome

Percentages
between control
and intervention
groups,
evaluations, drug
burden index
scores, Edmonton
frailty scale,
Stopp criteria

Level of evidence
Study contains both
SR with meta-analysis Level I
SR with descriptive studies Level V
Strengths: effectiveness of STOPP
screening to prevent ADEs, using
pharmacist and physician led education
and interventions
Limitations by range of health care
settings and study designs and small
sample sizes. Reveals gaps for future
research and interventions

Decreased
monthly
medication costs
Control group
differences

Resident
care
settings,
hospitals,
primary
care
centers,
communit
y
pharmaci
es, skilled
nursing
facilities,
adult day
centers

Primary
care

Burden index
scores

Recommendations: use STOPP
embedded into CDS tools as with the
recommendation of this study

Decreased
ADEs
Reduced PIMs

IV=depressio
n
multimorbidit

DBI

Kruskal-Wallis
test

Critical drug
reviews to reduce
issues with

Level of evidence=IV

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,
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Sinnige, J.,
Schellevis,
F., Taxis,
K., Van
Hattem, B.
A., &
Verhaak,
P.F.M.
(2017).
Late-life
depression
and the
association
with
multimorbi
dity and
polypharma
cy: a crosssectional
study.
Family
Practice,
34(5), 539545.

multimorbid
ity and
polypharma
cy could
help
practitioner
identify
patients at
risk for
adverse
drug-related
events

polypharma
cy. Findings
indicate
need for
regular Rx
reviews
using tools
like DBI

observatina
l method

Assess the
effect of a
CMR
focused on
personal
goals, QOL,
in older
person with
polypharma
cy

Randomizat
ion to
control and
intervention
groups

RCT
(Medline)

Data from
2012 using
three
databases
(NIVELPCD),
(SFK),
(CBS)

setting in
the
Netherlan
ds

ies,
polypharmacy
DV=DBI for
review to
prevent ADEs

ICPC codes
identify chronic
diseases

Mann-Whitney
U test

polypharmacy in
primary care
Alternative
treatments

Age, gender,
SES scores

Target patients
with chronic
diseases and
dpreession with
behavioral
intervention not
pharmacological
means

SES

Strengths=number of patients, dispensed
drugs rather than prescribed, routinely
recorded data
Limitations=correct coding by
physicians, misclassified mental health
Recommendations=using tools such as
DBI for Rx reviews

KS 6
Blom, J.
W., Bouvy,
M. L.,
Gussekloo,
J., Kwint,
H. F.,
Verdoorn,
S., (2019).
Effects of a
clinical
medication
review
focused on

Pharmacists
consulting
with PCPs
Numerous
follow-ups

CMR
focused on
personal
goals,
QOL, with
polypharma
cy
315intervention

N=707
out of
2290
35
pharmaci
es
12
different
health
problems

IVpolypharmacy
DV-personal
goals (PG),
QOL, health
problems

Polypharmacy
measured with
CMR
PG, QOL, health
problems
measured with
VAS & EQ-D5DL
Health problems
measured with a
questionnaire

S1 statistical
analysis plan
Descriptive
statistics for
patient
characteristics
Data analyzed
with IBM SPSS
statistics 24.0

CI-95%

Level of Evidence= II

Improvements in
QOL using EQVAS

Strengths-personalized goal setting that
was effective, study performed with
daily pharmacy practice, experienced
pharmacists, follow up with PCPs, to
prevent bias all questionnaires recorded
by independent research assistants

Reductions in the
number of health
problems that had
moderate to
severe impact on
DL

Weakness: blinding impossible, risk of
contamination, only 25% of 2290
participated, some goals may not have
been realistic

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,
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personal
goals,
quality of
life, and
health
problems in
older
persons
with
polypharma
cy: A
randomized
controlled
trial
(DREAMe
Rstudy). PLo
S
medicine, 1
6(5),
e1002798.

group 314control
group

Netherlan
ds

Reductions in
long-term Rx
CMR has effect
on patient goals
and preferences

≥70 yrs.
≥7 long
term
medications

Recommendations: More studies are
needed for the prevention of
polypharmacy. Pharmacists could
become more involved with this issue
using varieties of CMRs

Participants
recruited
from
4/20162/2017
Baseline/ 3months/6months

KS7
Piccoliori,
G.,
Mahlknecht
, A., Sandri,
M.,
Valentini,
M., Vögele,
A., Schmid,
S.,
Deflorian,
F., Engl,
A.,
Sönnichsen,
A., &
Wiederman
n, C.J.

Develop
strategies to
reduce
polypharma
cy and its
well known
harmful
consequenc
es

Study the
epidemiolog
y and
associated
factors of
polypharma
cy

Cross
sectional
study in
Italy using
2012 Beers
criteria to
access
DDIs and
PIMs. Data
analysed
with
descriptive
methods,
Wilcoxon
rank-sums,
Fishers and

270 GP
sample
n= 43
participati
ng
579
patients

patients ≥8
Rx and age
≥75yrs, no
terminal
illness,
excluding
PRN meds

Demographid/bi
ometric
characteristics,
diagnoses,
medication
related data,
cognitive/affecti
ve status.
Assessing DDIs
and PIMs

2012 Beers
criteria
Lexi-interact
database
Wilcoxon ranksums
Fisher’s exact
test
Spearman
correlations

Results of
polypharmacy
associated with
number of
chronic
conditions, higher
number of DDIs
and lower quality
of life

Level of evidence=IV
Limitations-OTC drug use, new drugs
prescribed by specialist may not yet be
in EHR, PRN medications excluded,
Strengths-ability to include
demographic and clinical
characteristics. Also medications
appropriateness and DDIs
Conclusion-GPs should keep patients
with multiple conditions, reduced
health, and combinations of certain
diagnoses under surveillance.

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,
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(2021).
Epidemiolo
gy and
associated
factors of
polypharma
cy in older
patients in
primary
care: a
northern
Italian
crosssectional
study. BMC
Geriatrics,
21.

Spearmans
correlations

This study is strong evidence of the
quality of life for patients who practice
polypharmacy. More tools need to be
placed in EHRs to help guard agains
DDI and PIM events.

KS 8
Laberge,
M., Sirois,
C., Lunghi,
C.,
Gaudreault,
M.,
Nakamura,
Y., Bolduc,
C., &
Laroche,
M. L.
(2021).
Economic
Evaluations
of
Interventio
ns to
Optimize
Medication
Use in

Conduct a
systematic
review of
economic
evaluation
of
intervention
s intended
at
optimizing
medication
use in
patients
with
multimorbic
ity and
polyphamra
cy to
determine if
intervention

Study
intervention
s aimed at
optimizing
medication
use and
present
results on
costs

SR
Multimorbi
dity with at
least two
chronic
conditions.
Rx ≥5 Rx
Published
articles
2004-2020

Multimor
bidity,
polyphar
macy,
3871
articles
identified
with 68
articles
eligible
for full
text
review

Polypharmacy
multimorbidit
y, older adults

Interventions
associated with
medicatin
expenditures

CEA, CUA,
CBA, QUALY,

11 studies met
criteria for full
economic
evaluation. Cost
effectiveness of
the intervention
depend on factors
of the
intervention and
willingness to pay
for thresholds for
marginal
improvements to
reduce ADEs

Level of Evidence = I
Strengths-in-depth search strategy
Limitations- relevant studies may have
been missed by not evaluating
relevancdes. Different definitions to
polypharmacy.
This study will be used to consider the
cost of interventions and cost
effectiveness. More research is also
needed to estimate the cost of
interventions

11
included
in study

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,
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Older
Adults with
Polypharma
cy and
Multimorbi
dity: A
Systematic
Review. Cli
nical
intervention
s in
aging, 16,
767–779.

s are cost
effective

KS 9
Muth, C.,
Blom, J.
W., Smith,
S. M.,
Johnell, K.,
GonzalezGonzalez,
A. I.,
Nguyen, T.
S.,
Brueckle,
M. S.,
Cesari, M.,
Tinetti, M.
E., &
Valderas, J.
M. (2019).
Evidence
supporting
the best
clinical
managemen
t of patients
with

Best clinical
managemen
t of patients
with
myltimorbid
ity and
polypharma
cy

Identify and
analyse
available
evidencebased
clinical
practice
guidelines
for
multimorbid
ity or
polypharma
cy

SR
Multistep
consensus
process
involving
multidiscipl
inary
experts
from seven
countries.

18multidisci
plinary
experts
from 7
countries
with an
extraction
of 250
recomme
ndatins.
Target
populatio
n (risk
factors)

Physiological
status and
frailty.
Review of
medication
enocunters
Risk factors
Medical
history

Ariadne
princples

Ariadne
framework
Quality of .
guidelines with
MiChe
checklist
Thematic
synthesis at a 2
day meeting

Need to patient
preferences and
goal setting,
expectations,
shared decision
making, treatment
options,
individualized
management,
followup
monitoring, care
plan strategies

Level of evidence = I
Limitations – themes selected and
presented
Strength – concluded that strong
guidelines for interventions in regards to
polypharmacy
Conclusion – this SR will be used to
highlight the need for further research to
appropriate interventions on
polypharmacy

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,
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multimorbi
dity and
polypharma
cy: a
systematic
guideline
review and
expert
consensus.
Journal of
internal
medicine, 2
85(3), 272–
288.
#10 Article
citation
(APA): Wu,
H.,
Kouladjian
O'Donnell,
L., Fujita,
K.,
Masnoon,
N., &
Hilmer, S.
N. (2021).
Deprescribi
ng in the
older
patient: A
narrative
review of
challenges
and
solutions.
Internation
al Journal
of General
Medicine,

provide a
narrative
review of
the safety
and efficacy
of
deprescribin
g
intervention
s,
challenges
and
solutions of
deprescribin
g research
and
implementat
ions in
clinical
practice, the
benefits of
using
computerize
d clinical

Using the
studies
with the
met
criteria for
deprescrib
ing
methods,
the theory
is stated as
polypharm
acy is a
major
challenge
in
healthcare
for older
people
with
associated
risks of
adverse
outcomes.
The

Mixed
method
Literature
Review

DV
Literature
search
focusing
on
systemati
c reviews
published
from
1/1/2016
to
3/1/2021.
Using
search
terms
deprescri
bing,
polyphar
macy,
PIMs,
challenge
s,
barriers,

polypharmacy
,
deprescribing,
PIMs
IV barriers,
quality
indicator,
clinical
indicator,
performance
measures,
obstacles

Systematic
reviews
analyzed by
authors

Search strategy
to review
abstracts and
title of each
publication
were reviewed
to determine
their relevance
to research
questions.
Reviews were
included if they
fulfilled the
following
criteria.

Inappropriate
medications
contribute to
morbidity and
mortality.
Deprescribing is
an established
management
strategy to
minimize
polyphamracy

Level of Evidence =1
Strengths: plan-do-study-act cycles to
facilitate deprescribing for
polypharmacy
Limitations: not a systematic review of
systematic reviews. Limitations of
traditional narrative reviews, risk for
bias, overlaing reviews.
Conclusion: this review contains many
of the key elemants that are related to
the polypharmacy and deprescribing

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,
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Volume 14,
3793–3807.
https://doi.o
rg/10.2147/
ijgm.s2531
77

decision
support
systems and
quality
indicators
(QIs) in
deprescribin
g in
research
and practice

review
highlights
the
interest in
deprescrib
ing in
reducing
medicatio
n related
harms in
older
individual
s.

obstacles,
quality
indicator,
clinical
indicator,
performa
nce
measures,
aged
older,
geriatric.
83
systemati
c reviews
and a
narrative
summary
performe
d

#11
MartinezGomez, D.,
GuallarCastillon,
P.,
HiguerasFresnillo,
S.,
Banegas, J.
R.,
Sadarangan
i, K. P., &
RodriguezArtalejo, F.
(2018). A
healthy
lifestyle

Level IV

The purpose
of the study
was to the
study
analysed
4yrs of a
hospital
register
2015-2018
to
determine
the risk of
30-day
hospital
readmission

Health
expectanc
y can be
attributed
to
healthcare
including
pharmacu
etical
treatments
and age
related
chronic
diseases is
related to

Cohort
Study

4008 with
83
excluded,
stratified
then
randomly
from
clusters,
then
selected
by sex
and age
strata. Six
lifestyles
considere
d

IV:
polypharmacy
, lifestyle,
sex, age,
education
level,
mortality rate
DV: number
of
medications,
behaviors

Kaplan-Meier
method to
calculate
lifestyle
behaviors
Cox
proportion
al hazards
regression
s to
measure
hazard
ratios
Log-rank tests
to
measure
assess
difference

Sex/age
Education,
BMI, BP,
mental state,
agility, chronic
diseases
electronic
health records
of 20,422
inpatient stays
of
polymedicated
home dwelling
older adults

Health
expectancy
can be
attributed to
the
effectiveness
and coverage
of health care
including
pharmacologic
al treatments
but the agerelated chronic
conditions has
resulted in
increases in
the number of

Strengths: Large representative sample.
Variable collected by trained staff using
standardized methods. Consistency
Limitations: cofoiunding and
associations may not implify causation.
Self reported lifestyles which may cause
bias. Lifestyle and drug treatments were
obtained at baseline
Recommendation: will use this study
toward the capstone as it has many of
the key factors associated with study.

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,

28

Polypharmacy Teaching in the Acute Setting Benchmark Study
attenuates
the effect of
polypharma
cy on total
and
cardiovascu
lar
mortality: a
national
prospective
cohort
study. Scien
tific
reports, 8(1
), 12615.
https://doi.o
rg/10.1038/
s41598018-308409

#12
Health
expectan
cy can
be
attribute
d to the
effective
ness and
coverage
of health
care

associated
with the
medical
conditions
and drug
regimens of
polymedicat
ed, older
inpatients
discharged
home

The purpose
of the study
was to the
study
analysed
4yrs of a
hospital
register
2015-2018
to
determine
the risk of

polypharm
acy.
Polyphar
macy
associated
with
ADEs.
Healthy
lifestyles
show to
improve
QOL and
reducing
medicatio
ns

Examine
d the
records
of 20422
over a
four year
period of
hospitali
zations
involvin
g

smoking,
diet, etoh
consumpt
ion,
physical
activity,
sedentary
behavior,
and sleep
duration.
Education
levels
were
recorded,
medicatio
ns
classified
by 3
categories
0-1
medicatio
ns, 2-4
medicatio
ns, then
≥5
medicatio
ns

Quantitativ
e Cohort
Study

20,422
electronic
health
records
and
13,802
patients
identified
with
sociodem

s in
lifestyle
behaviors

IV:
Sociodemogra
phic and
clinical data
DV 30 day
readmission

Polypharmacy
and
multimorbidity
used for this
research,
appropriate to
answer research
question

held in the
hospital’s
register and
identify
polymedicated
multimorbid
patients
readmitted
within 30 days
of discharge.

Data extracted
into Microsoft
Excel
spreadsheet.
Then imported
into SPSS
V.26.0 software
ICD codes and
CHOP
interventions
and drug
prescriptions

medications,
known as
polypharmacy.
A healthy
lifestyle has
been shown to
improve health
in older adults,
therefore, it is
of interest to
assess whether
the adverse
mortality
effect of
polypharmacy
could be
reduced by a
healthy
lifestyle.

CI=95%
Evidence IV
Readmissions
patterns are
comples,
poorly
understoodolder patients
are often comorbid and
have complex

Strengths: the data recorded in a
comprehensive register
Limitations: could not identify
hospitalizations and readmits lost to
follow-up and death outside of the
hospital. And readmitted from another
hospital.

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,
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includin
g
pharmac
ological
treatmen
ts but the
agerelated
chronic
conditio
ns has
resulted
in
increases
in the
number
of
medicati
ons,
known
as
polyphar
macy.
Which
has been
associate
d with
adverse
health
outcome
s, poor
treatmen
t
adherenc
e,
adverse
drug
reactions
and

30-day
hospital
readmission
associated
with the
medical
conditions
and drug
regimens of
polymedicat
ed, older
inpatients
discharged
home

polyphar
macy in
older
adults.
Then
identify
the risk
of
multimor
bid
patients
practicin
g
polyphar
macy for
readmiss
ion
within
thirty
days.

ographic
characteri
stics,
medical
condition
s,
readmissi
ons and
polyphar
macy

during hospital
stay

drug
prescriptions

Recommendations: I will use this study,
it has several key factors which are
included in the capstone study.

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,
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events,
falls,
fractures
,
cognitiv
e
function
impairm
ent, and
hospitali
zations.
A
healthy
lifestyle
has been
shown to
improve
health in
older
adults,
therefore
, it is of
interest
to assess
whether
the
adverse
mortality
effect of
polyphar
macy
could be
reduced
by a
healthy
lifestyle.

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,
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ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUA-cost utility analysis, DBI-drug burden index, CIconfidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent
variable, HP-health promotion, HP-hypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions, NIVEL-PCDNetherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control trial, SKF-foundation of pharmaceutical statistics, SR-systematic review,
STOPP- screening tool of older persons potentially inappropriate prescriptions,

Appendix B
Timetable/Flowchart
I. Required education to be completed before PI project implementation (class session and
modules)
II. Patient admitted to ED
III. Medication reconciliation (Recognize Polypharmacy)(Recognize ADEs) This helps alleviate
the possible prescription duplication or prescription synergistic or antagonistic effects of new Rx
(Charge nurse rounding)
IV. Polypharmacy is recognized when a patient takes five or more prescriptions, the nurse
notifies the ED physician or hospitalist, and the charge nurse
V. The nurse will determine the patient, family, or caretaker’s understanding of medications. Is
more intervention needed?
VI. Discharge from ED or inpatient setting with a clear understanding of all medications,
including new discharge medications. Provide education materials when discharged and arrange
a follow-up appointment with the primary care physician when discharged from the inpatient
setting
VII. Notify primary care physician of ED visit (this is done unless the patient refuses at check-in)
VIII. Follow up with phone calls within two weeks of discharge (done by the assigned ED nurse,
a case manager in the inpatient setting). Percentage rate of patients who retained education of
polypharmacy vs. those patients who did not
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IX. After a 13-week implementation of this project, chart audits and compare percentages of
admits with ADEs before implementation

ADE- Adverse drug event, CBS-statistics of Netherlands, CBA-cost benefit analysis CC-coordinated care, CEA-cost-effective analysis, CUAcost utility analysis, DBI-drug burden index, CI-confidence interval, DDI- drug-to-drug interactions, DV-dependent variable, ICD-international
classification of diseases IV-independent variable, MDT-multi drug therapy, OR-Odds ratioDV-dependent variable, HP-health promotion, HPhypothetical profile, IQ-interview questions, IV-independent variable, PCS-primary care setting, PIM-potentially inappropriate prescriptions,
NIVEL-PCD-Netherlands institute of health services research primary care database, QALY-quality-adjusted life years, RCT-random control
trial, SKF-foundation of pharmaceutical statistics, SR-systematic review, STOPP- screening tool of older persons potentially inappropriate
prescriptions,

